E-ISSN 2148-5607
RELATED ARTICLES
Editorial
Effects of Giardia lamblia infestation on the clinical sourse of cronic hepatitis B
(Turk J Gastroenterol 1998; 9: 24-27)
Acral erythema induced bu interferon alpha in a child
(Turk J Gastroenterol 1998; 9: 70-72)
Daily consensus interferon (CIFN) monotherapy in non-responders or relapsers to a previous interferon regime: One year follow-up after 48 weeks of treatment
(Turk J Gastroenterol 2006; 17: 35-39)
The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients
(Turk J Gastroenterol 2006; 17: 94-98)
An asymptomatic huge hepatocellular carcinoma with intra-atrial tumor thrombus in a patient with chronic hepatitis B viral infection
(Turk J Gastroenterol 2006; 17: 203-205)
Assessment of bone metabolism and mineral density in chronic viral hepatitis
(Turk J Gastroenterol 2006; 17: 260-266)
Immunomodulatory effects of HBsAg vaccine and levamisole in chronic hepatitis B and hepatitis B carrier children
(Turk J Gastroenterol 2005; 16: 188-193)
Effect of interferon treatment on glucose metabolism in children with chronic hepatitis B infection
(Turk J Gastroenterol 2004; 15: 4-10)
Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha
(Turk J Gastroenterol 2004; 15: 213-218)
Predictive value of proliferating cell nuclear antigen index in response to interferon treatment in patients with chronic viral hepatitis B and C
(Turk J Gastroenterol 2001; 12: 89-94)
The effect of recombinant hepatitis B vaccine therapy in chronic hepatitis B infection
(Turk J Gastroenterol 2002; 13: 6-10)
Determination of serum hepatitis B virus DNA in chronic HBsAg carriers: Clinical significance and correlation with serological markers
(Turk J Gastroenterol 2003; 14: 157-163)
A comparative immunohistochemical study of HBsAg, HBcAg and CD57 in chronic hepatitis B pediatric patients with and without malignant disorders
(Turk J Gastroenterol 2003; 14: 234-238)
Evaluation of the outcome of interferon therapy in chronic hepatitis B infection
(Turk J Gastroenterol 1999; 10: -)
Transmission routes of chronic hepatitis C and their relation to HCV genotypes
(Turk J Gastroenterol 2010; 21: 396-400)
DOI: 10.4318/tjg.2010.0126
Determination of intracellular Th1/Th2 type cytokines in lymphocytes of chronic hepatitis B patients treated with interferon-alpha
(Turk J Gastroenterol 2010; 21: 401-410)
DOI: 10.4318/tjg.2010.0127
Relationship between serum levels of interleukin-10, interleukin-2 and soluble intercellular adhesion molecule-I and liver injury in chronic hepatitis B virus infection
(Turk J Gastroenterol 1999; 10: 243-248)
HCV genotypes in HCV related chronic hepatitis in Southeast Anatolia
(Turk J Gastroenterol 1999; 10: 249-252)
Review
Emerging therapeutics and relevant targets for chronic Hepatitis B
(Turk J Gastroenterol 2016; 27: 210-215)
DOI: 10.5152/tjg.2016.15521
Case Report
A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B
(Turk J Gastroenterol 2014; 25: 206-209)
DOI: 10.5152/tjg.2014.3605
A case of gynecomastia due to entecavir
(Turk J Gastroenterol 2010; 21: 313-316)
DOI: 10.4318/tjg.2010.0108
Original Article
Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients
(Turk J Gastroenterol 2012; 23: 538-545)
DOI: 10.4318/tjg.2012.0358
AST-platelet ratio index in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis B
(Turk J Gastroenterol 2012; 23: 353-358)
DOI: 10.4318/tjg.2012.0348
Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B
(Turk J Gastroenterol 2012; 23: 247-252)
DOI: 10.4318/tjg.2012.0380
AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2011; 22: 279-285)
DOI: 10.4318/tjg.2011.0213
Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
(Turk J Gastroenterol 2016; 27: 55-61)
DOI: 10.5152/tjg.2015.150280
The predictive value of noninvasive serum markers of liver fibrosis in patients with chronic hepatitis C
(Turk J Gastroenterol 2016; 27: 156-164)
DOI: 10.5152/tjg.2015.150449
The association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C: An observational, multicenter study in Turkey
(Turk J Gastroenterol 2014; 25: 546-552)
DOI: 10.5152/tjg.2014.7829
Liver - Original Article
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey
(Turk J Gastroenterol 2019; 30: 331-335)
DOI: 10.5152/tjg.2018.18269
Assessing the outcome of patients with liver cirrhosis during hospital stay: A comparison of lymphocyte/monocyte ratio with MELD and Child-Pugh scores
(Turk J Gastroenterol 2018; 29: 308-315)
DOI: 10.5152/tjg.2018.17631
Does steatosis affect the performance of diffusion-weighted MRI values for fibrosis evaluation in patients with chronic hepatitis C genotype 4?
(Turk J Gastroenterol 2017; 28: 283-288)
DOI: 10.5152/tjg.2017.16640
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
(Turk J Gastroenterol 2018; 29: 464-472)
DOI: 10.5152/tjg.2018.16597
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study
(Turk J Gastroenterol ; : -)
DOI: 10.5152/tjg.2018.16597
Poster
Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience
(Turk J Gastroenterol 2019; 30: 10-15)
DOI: 10.5152/tjg.2019.07
Successfully treatment of chronic hepatitis C with direct-acting antiviral agents: a single center experience
(Turk J Gastroenterol 2019; 30: 34-34)
DOI: 10.5152/tjg.2019.20
Efficacy of entecavir treatment for up to 5 years in patients with HBV-related compensated cirrhosis in Turkey; real life data
(Turk J Gastroenterol 2019; 30: 36-36)
DOI: 10.5152/tjg.2019.22
Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection
(Turk J Gastroenterol 2019; 30: 43-45)
DOI: 10.5152/tjg.2019.28
Evaluation of 24-year followig results of patients with inactive hepatitis B
(Turk J Gastroenterol 2019; 30: 55-55)
DOI: 10.5152/tjg.2019.35
A case with chronic HBV infection who was non-responder to nucleos(t)ide analogues was treated with Pegylated interferon
(Turk J Gastroenterol 2019; 30: 70-72)
DOI: 10.5152/tjg.2019.47
Clinical and laboratory features of children with chronic hepatitis B infection: A single center results
(Turk J Gastroenterol 2019; 30: 74-74)
DOI: 10.5152/tjg.2019.49
Clinical outcomes after cessation of potent antiviral treatment in chronic hepatitis B patients
(Turk J Gastroenterol 2019; 30: 81-82)
DOI: 10.5152/tjg.2019.54
Poster Presentation
The evaluation of liver biopsy specimens of chronic hepatitis B patients using early tissue markers for Hepatocellular Carcinoma: Before and after the development of Hepatocellular Carcinoma
(Turk J Gastroenterol 2019; 30: 102-102)
DOI: 10.5152/tjg.2019.67
Key Words
Authors
All
Reviewer's Corner
Author’s Corner
Survey
AVES | Copyright © 2019 Turkish Society of Gastroenterology | Latest Update: 30.05.2019